Surgical Science Sweden (SUS) Stock Overview
Develops and markets virtual reality simulators for evidence-based medical training in Europe, North and South America, Asia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
SUS Community Fair Values
Create NarrativeSee what 20 others think this stock is worth. Follow their fair value or set your own to get alerts.
Surgical Science Sweden AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 33.52 |
| 52 Week High | SEK 192.40 |
| 52 Week Low | SEK 24.00 |
| Beta | 0.60 |
| 1 Month Change | -58.26% |
| 3 Month Change | -63.86% |
| 1 Year Change | -77.68% |
| 3 Year Change | -78.94% |
| 5 Year Change | -61.29% |
| Change since IPO | 191.48% |
Recent News & Updates
Surgical Science Sweden AB (publ) (STO:SUS) Might Not Be As Mispriced As It Looks After Plunging 66%
Nov 27
Surgical Science Sweden AB (publ) Just Missed Earnings - But Analysts Have Updated Their Models
Nov 16Recent updates
Surgical Science Sweden AB (publ) (STO:SUS) Might Not Be As Mispriced As It Looks After Plunging 66%
Nov 27Surgical Science Sweden AB (publ) Just Missed Earnings - But Analysts Have Updated Their Models
Nov 16Surgical Science Sweden's (STO:SUS) Conservative Accounting Might Explain Soft Earnings
Aug 31Earnings Miss: Surgical Science Sweden AB (publ) Missed EPS And Analysts Are Revising Their Forecasts
Aug 24What You Can Learn From Surgical Science Sweden AB (publ)'s (STO:SUS) P/E After Its 32% Share Price Crash
Aug 20The Price Is Right For Surgical Science Sweden AB (publ) (STO:SUS) Even After Diving 27%
Mar 14Surgical Science Sweden's (STO:SUS) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Mar 01
Regulatory Approvals For New Robotics Entrants Will Drive Demand For Simulation Products
Strength in the Educational Products segment and rising demand for simulators indicate potential revenue growth and diversification opportunities.The Price Is Right For Surgical Science Sweden AB (publ) (STO:SUS)
Nov 12Surgical Science Sweden AB (publ) Just Missed EPS By 22%: Here's What Analysts Think Will Happen Next
Aug 25Earnings Beat: Surgical Science Sweden AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Apr 21Here's Why Surgical Science Sweden (STO:SUS) Has Caught The Eye Of Investors
Apr 16Surgical Science Sweden AB (publ)'s (STO:SUS) Share Price Is Still Matching Investor Opinion Despite 25% Slump
Mar 17Results: Surgical Science Sweden AB (publ) Beat Earnings Expectations And Analysts Now Have New Forecasts
Feb 24Is There Now An Opportunity In Surgical Science Sweden AB (publ) (STO:SUS)?
Nov 29Should You Be Adding Surgical Science Sweden (STO:SUS) To Your Watchlist Today?
Oct 07Is Surgical Science Sweden AB (publ) (STO:SUS) Trading At A 39% Discount?
Aug 17With EPS Growth And More, Surgical Science Sweden (STO:SUS) Makes An Interesting Case
Jun 20A Look At The Fair Value Of Surgical Science Sweden AB (publ) (STO:SUS)
May 17Surgical Science Sweden AB (publ) (STO:SUS) Shares Could Be 49% Below Their Intrinsic Value Estimate
Dec 27Is Now The Time To Put Surgical Science Sweden (STO:SUS) On Your Watchlist?
Dec 06Is Now The Time To Look At Buying Surgical Science Sweden AB (publ) (STO:SUS)?
Sep 08We Ran A Stock Scan For Earnings Growth And Surgical Science Sweden (STO:SUS) Passed With Ease
Aug 23Surgical Science Sweden AB (publ) (STO:SUS) Shares Slammed 33% But Getting In Cheap Might Be Difficult Regardless
May 26Here's Why We Think Surgical Science Sweden (STO:SUS) Is Well Worth Watching
Apr 29Shareholder Returns
| SUS | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | -2.6% | -0.6% | 1.0% |
| 1Y | -77.7% | -21.7% | 2.0% |
Return vs Industry: SUS underperformed the Swedish Medical Equipment industry which returned -21.2% over the past year.
Return vs Market: SUS underperformed the Swedish Market which returned 1.8% over the past year.
Price Volatility
| SUS volatility | |
|---|---|
| SUS Average Weekly Movement | 17.9% |
| Medical Equipment Industry Average Movement | 7.4% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in SE Market | 11.4% |
| 10% least volatile stocks in SE Market | 3.0% |
Stable Share Price: SUS's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: SUS's weekly volatility has increased from 11% to 18% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 328 | Tom Englund | www.surgicalscience.com |
Surgical Science Sweden AB (publ) develops and markets virtual reality simulators for evidence-based medical training in Europe, North and South America, Asia, and internationally. The company offers Angio Mentor simulator for endovascular training; BRONCH Express, a portable version of BRONCH mentor simulator; ARTHRO Mentor for arthroscopic surgery skills acquisition; BRONCH Mentor, a simulator for optimizing bronchoscopy training; GI Mentor, a simulator for GI Endoscopy; HYST Mentor for True-To-Life diagnostic and therapeutic hysteroscopy training; URO Mentor, a virtual reality simulator for endourology training; EndoSim, a realistic scope simulator; FlexVR, a flexible and portable training platform which is designed to teach basic and advanced skills for robotic surgery; and LAP Mentor provides a wide array of laparoscopic training cases. It also provides LapSim training system comprising LapSim Haptic simulator that provides laparoscopic training; LapSim essence, a portable and ready-to-use VR simulator; and LapSim 360, which provides a high-immersion virtual reality training experience; MentorLearn, an end-to-end educational platform that makes simulation course management; and LapSim ST, a state-of-the-art training system that prepares students for the operating room.
Surgical Science Sweden AB (publ) Fundamentals Summary
| SUS fundamental statistics | |
|---|---|
| Market cap | SEK 1.71b |
| Earnings (TTM) | SEK 69.83m |
| Revenue (TTM) | SEK 975.04m |
Is SUS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SUS income statement (TTM) | |
|---|---|
| Revenue | SEK 975.04m |
| Cost of Revenue | SEK 325.54m |
| Gross Profit | SEK 649.50m |
| Other Expenses | SEK 579.67m |
| Earnings | SEK 69.83m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Feb 19, 2026
| Earnings per share (EPS) | 1.37 |
| Gross Margin | 66.61% |
| Net Profit Margin | 7.16% |
| Debt/Equity Ratio | 0.04% |
How did SUS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/08 12:44 |
| End of Day Share Price | 2025/12/05 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Surgical Science Sweden AB (publ) is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Simon Jonsson | Berenberg |
| Viktor Högberg | Danske Bank |
| Simon Larsson | Danske Bank |